10-K: Hims & Hers Reports Strong Revenue Growth Amidst Regulatory Scrutiny

Hims & Hers Health, Inc. announced significant revenue and Adjusted EBITDA growth for 2025, alongside international expansion and new product launches, but faces increasing regulatory and legal challenges.

Summary

• Total revenue for the year ended December 31, 2025, increased by 59% to $2,347.6 million, up from $1,476.5 million in 2024.
• United States revenue grew by 53% to $2,213.6 million, while Rest of the World revenue surged by 399% to $134.0 million, driven by recent acquisitions.
• Online revenue increased by 61% to $2,311.4 million, primarily from subscription-based personalized offerings.
• Subscribers grew by 13% to approximately 2,511,000 as of December 31, 2025.
• Monthly Revenue per Average Subscriber increased by 28% to $83, largely due to personalized offerings and product mix changes.
• Net income for 2025 was $128.4 million, a modest increase from $126.0 million in 2024.
• Adjusted EBITDA saw a substantial increase of 79.7% to $318.0 million in 2025, up from $176.9 million in 2024.
• Gross margin decreased to 74% in 2025 from 79% in 2024, mainly due to weight loss offerings having higher product, packaging, and shipping costs, and the impact of international business growth.
• Free Cash Flow significantly decreased to $57.4 million in 2025 from $198.3 million in 2024.
• The company completed acquisitions of Zava (UK/EU digital health) and Medici (Canadian digital health) in 2025, and YourBio Health (blood sampling technology) in January 2026.
• A definitive agreement to acquire Eucalyptus, an Australia-based digital health company, for up to $1.15 billion was announced in February 2026, expected to close mid-2026.
• The company received FDA warning letters in September 2025 regarding compounded GLP-1 products and was directly named in a February 2026 FDA statement intending to restrict GLP-1 APIs for non-FDA-approved compounded drugs.
• HHS referred the company to the DOJ in February 2026 for potential violations of the Federal Food, Drug, and Cosmetic Act and Title 18 provisions.
• The SEC opened an investigation in February 2026 concerning public statements and disclosures regarding compounded semaglutide and related business relationships.
• Novo Nordisk filed a patent infringement lawsuit in February 2026 related to compounded GLP-1 products containing semaglutide.
• A cybersecurity incident was identified in early February 2026, where an unauthorized third party accessed the customer service software platform and obtained certain PII, but electronic medical records were not accessed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative filing. While strong revenue and Adjusted EBITDA growth are positive, the significant decline in Free Cash Flow and the emergence of multiple, serious regulatory and legal challenges related to its core growth area (GLP-1s) introduce considerable uncertainty and potential future costs, offsetting the strong operational performance.

Positives

• Total revenue increased by 59% to $2,347.6 million in 2025, demonstrating strong top-line growth.
• Adjusted EBITDA grew by 79.7% to $318.0 million, indicating improved operational efficiency and profitability on an adjusted basis.
• Net income increased to $128.4 million in 2025, marking continued profitability.
• International expansion through acquisitions of Zava and Medici significantly boosted Rest of the World revenue by 399%.
• Personalized offerings now represent over 70% of United States revenue, showing successful product diversification and customer adoption.
• The Hers brand's contribution to United States revenue increased to nearly 40%, driven by GLP-1s and dermatology offerings.
• Subscriber base grew by 13% to over 2.5 million, indicating continued customer acquisition.
• Successful Super Bowl marketing campaign in Q1 2025 enhanced brand awareness and drove new customer growth.
• The company has a strong liquidity position with $928.8 million in cash, cash equivalents, and available-for-sale investments as of December 31, 2025.
• The 2025 Share Repurchase Program authorized up to $250.0 million, with $225.0 million remaining available, signaling confidence in valuation and commitment to shareholder returns.

Negatives

• Gross margin decreased to 74% in 2025 from 79% in 2024, primarily due to higher costs associated with weight loss offerings and international business growth.
• Free Cash Flow decreased significantly by 71% to $57.4 million in 2025 from $198.3 million in 2024, indicating increased capital expenditures and investment activities.
• Wholesale revenue decreased by 6% to $36.2 million in 2025, suggesting a decline in this segment.
• Increased operating expenses across all categories (marketing, operations and support, technology and development, general and administrative) due to investments in growth and acquisitions.
• The company's Outsourcing Facility received an FDA warning letter in December 2025 for adverse event reporting deficiencies.
• The FDA resolved the semaglutide shortage in February 2025, limiting the company's ability to use 503B outsourcing facilities for compounded semaglutide, potentially constraining supply and increasing costs.
• A cybersecurity incident in early February 2026 resulted in unauthorized access to customer service software and certain PII, posing reputational and potential financial risks.

Risks

• Inability to maintain profitability due to continued investments in growth, platform expansion, and operating as a public company.
• Fluctuations in quarterly and annual results of operations due to new offerings, marketing effectiveness, pricing, and regulatory changes.
• Inability to expand or maintain the scope of offerings, including product types, provider quality, and treatable conditions, potentially due to regulatory changes or market acceptance.
• Failure to successfully market to new customers and retain existing ones, or limitations on marketing activities due to evolving privacy, healthcare, or other regulations.
• Operating in highly competitive markets with larger, well-established healthcare providers, retailers, pharmaceutical companies, and technology companies.
• Damage to brand reputation due to unexpected side effects, safety concerns, litigation, regulatory proceedings, negative publicity, or actions of influencers.
• Dependence on relationships with Affiliated Medical Groups, which are not owned by the company, for healthcare consultation services, with risks of disruption due to disputes or regulatory non-compliance.
• Inability of Affiliated Medical Groups to attract and retain high-quality Providers, or failure to maintain satisfactory relationships with Providers or Affiliated Medical Groups.
• Risks of professional liability claims against Affiliated Medical Groups, Providers, Partner Pharmacies, Facilities, and Manufacturing Suppliers, potentially exceeding insurance coverage.
• Adverse effects on business if Providers are reclassified as employees instead of independent contractors, leading to significant additional expenses.
• Operating difficulties, dilution, and other harmful consequences from acquisitions and investments, including challenges in integration and realization of anticipated benefits.
• Additional business, political, legal, regulatory, operational, financial, and economic risks from international expansion, including the Proposed Acquisition of Eucalyptus.
• Adverse effects from economic uncertainty or downturns, particularly impacting customer spending on discretionary health and wellness offerings.
• Inability to deliver a rewarding experience on mobile devices, impacting customer attraction and retention.
• Disruption to continued and unimpeded access to the internet and mobile networks, or service interruptions from third-party providers like Amazon Web Services.
• Dependence on third parties (Affiliated Medical Groups, Partner Pharmacies, Manufacturing Suppliers, cloud providers, payment processors) for critical functions, with risks of supply chain disruptions or termination of relationships.
• Increased complexity and compliance obligations due to pharmacy business operations and evolving healthcare laws and regulations.
• Risks associated with the payments system, including reliance on third-party service providers and compliance with complex, evolving laws and regulations.
• Adverse effects from pricing decisions on customer attraction, revenue, and profitability.
• Disruption to business if key management team members are lost or if effective succession plans are not in place.
• Inability to hire, integrate, develop, motivate, and retain personnel, particularly in competitive areas like machine learning and artificial intelligence.
• Damage or disruption at Facilities or third-party logistics providers, impacting inventory and product delivery.
• Failure to comply with applicable healthcare and other laws and governmental regulations, leading to substantial penalties, restructuring, or adverse effects on business.
• Actions and public statements by U.S. federal and state government officials and agencies, potentially leading to investigations, enforcement actions, and reputational harm.
• Product liability claims, contamination, mislabeling, recalls, or errors in dispensing/packaging of drugs, leading to injury, lawsuits, and reputational damage.
• Disruption from catastrophic events and man-made problems, such as power disruptions, data security breaches, and terrorism.
• Inability to maintain profitability in future fiscal periods due to increasing costs and investments.
• Reliance on subscription-based prescription products and services in the United States, with risks if offerings are not successfully expanded or if demand declines.
• Strain on resources, diversion of management attention, and potential litigation due to requirements of being a public company.
• Adverse effects from changes in accounting rules, assumptions, or judgments.
• Inability to obtain additional capital on acceptable terms, if at all, to support business growth.
• Adverse effects if estimates or judgments relating to significant accounting policies prove incorrect.
• Additional tax liability and increased costs from adverse tax laws or regulations, or their application to the company or customers.
• Concentration of voting power with CEO Andrew Dudum due to dual-class common stock structure, limiting investor influence.
• Volatility in the market price of Class A common stock due to industry changes, operating performance, research reports, litigation, and economic conditions.
• Potential for significant drop in stock price due to sale or perception of future sales of a substantial number of Class A common stock shares.
• Adverse effects on stock price and trading volume if analysts downgrade stock or publish inaccurate/unfavorable research.

Future Outlook

The company expects to continue investing in long-term growth, including expanding fulfillment and operating capabilities, marketing, product offerings, and customer experience. Revenue from personalized offerings is anticipated to increasingly drive total revenue growth. The company plans to pursue further acquisitions and investments in complementary businesses, services, and technologies, including intellectual property rights. International expansion remains a core pillar of the long-term growth strategy, with the acquisition of Eucalyptus expected to close in mid-2026. The company believes existing cash resources and the Revolving Credit Facility are sufficient to support planned operations for at least the next 12 months.

Management Comments

• Management believes the company has the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format.
• Management believes the integrated technology platform provides cost advantages that allow the company to offer affordable prices and generate robust gross margins.
• Management intends to continue to invest in growth in current offerings and additionally in new products and services.
• Management believes the Facilities enable seamless drug delivery and supply chain oversight, and drive increased operating leverage.
• Management views marketing capabilities as a core strength and key differentiator.
• Management believes that celebrating varied approaches and perspectives allows the company to better meet the challenge of providing access to affordable, accessible, personalized health and wellness solutions.
• Management believes that the expectations reflected in the forward-looking statements are reasonable, but cannot guarantee future results.

Industry Context

StockSavvy.ai notes that Hims & Hers' strong revenue growth and international expansion align with the broader trend of increasing adoption of telehealth and personalized digital health solutions. The company's focus on chronic conditions like sexual health, hair loss, and weight management, including GLP-1s, positions it in high-demand segments of the market. However, the intensified regulatory scrutiny from the FDA, HHS, and SEC, along with patent infringement lawsuits from established pharmaceutical players like Novo Nordisk, highlights the growing competitive and regulatory challenges faced by direct-to-consumer telehealth companies, particularly those involved in compounded medications. The decrease in gross margin and significant drop in Free Cash Flow, despite strong top-line growth, suggest that aggressive expansion and regulatory compliance costs are impacting profitability and liquidity, a common challenge for rapidly scaling companies in highly regulated sectors.

Comparison to Industry Standards

• Hims & Hers' 59% revenue growth significantly outpaces many traditional healthcare providers and even some digital health competitors, indicating strong market penetration and demand for its direct-to-consumer model.
• The 79.7% Adjusted EBITDA growth suggests superior operational leverage compared to many early-stage digital health companies, demonstrating effective cost management in scaling non-GAAP profitability.
• The decline in gross margin from 79% to 74% is notable, especially when compared to some pure-play software-as-a-service (SaaS) telehealth platforms that typically maintain higher gross margins (e.g., Teladoc Health's BetterHelp segment often reports gross margins above 70-75%). This suggests the company's integrated pharmacy and compounding model, particularly with GLP-1s, introduces higher cost of goods sold.
• The substantial decrease in Free Cash Flow from $198.3 million to $57.4 million is a concern, especially when compared to more mature, cash-generative healthcare companies. This indicates heavy investment in infrastructure (e.g., manufacturing facilities like C S Bio Co. assets) and acquisitions (Zava, Medici, YourBio, Eucalyptus), which is typical for growth-stage companies but warrants close monitoring for capital efficiency.
• The regulatory and legal challenges, including FDA warning letters and a patent lawsuit from Novo Nordisk, are specific to the compounded GLP-1 market. This level of direct regulatory and legal pressure is higher than what many general telehealth platforms face, placing Hims & Hers in a more litigious and scrutinized environment akin to pharmaceutical manufacturers rather than just service providers.

Management Changes

Corporate Governance

Legal Proceedings

• Federal Trade Commission (FTC) Civil Investigative Demand (October 2023) regarding privacy, advertising, and cancellation practices; company believes responses are substantially completed, no material impact expected.
• Consolidated securities class action lawsuits (June 25, 2025, amended January 29, 2026) alleging securities law violations related to misrepresentations about business, operations, prospects, and relationship with Novo Nordisk; company does not consider a loss probable.
• Putative shareholder derivative lawsuits (July-August 2025) against directors and executives, related to the securities actions, alleging breaches of fiduciary duty; proceedings are stayed, company does not consider a loss probable.
• Novo Nordisk A/S and Novo Nordisk Inc. patent infringement lawsuit (February 9, 2026) in U.S. District Court for the District of Delaware, related to compounded GLP-1 products containing semaglutide; seeks damages and permanent injunction.
• FDA warning letters (September 2025) regarding statements on websites concerning compounded semaglutide products; company responded.
• FDA warning letter (December 2025) to the company's Outsourcing Facility for failure to submit an adverse event report and deficiency in reporting procedures; company responded and is taking corrective actions.
• FDA statement (February 2026) indicating intent to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, directly naming the company.
• HHS General Counsel statement on X (February 2026) referring the company to the Department of Justice (DOJ) for investigation for potential violations of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.
• Securities and Exchange Commission (SEC) investigation (February 2026) opened, requesting documents and information concerning public statements and disclosures regarding compounded semaglutide and related business relationships.

Related Party Transactions

• Payments of $2.7 million in 2025, $4.1 million in 2024, and $2.1 million in 2023 to Woolly Labs, Inc. (d/b/a Vouched), a former related-party company providing identity verification services, which ceased to be a related party as of July 1, 2025.
• Payments of $4.6 million in 2023 to Terminal, Inc., a former related-party company providing professional services, which ceased to be a related party as of January 1, 2024.

Stakeholder Impact

• Shareholders: Potential dilution from future equity issuances for acquisitions, impact from share repurchase programs, and volatility in stock price due to market factors and legal/regulatory proceedings. Concentrated voting power with CEO Andrew Dudum limits influence.
• Customers: Continued access to a broader range of personalized health and wellness solutions, including new specialties and international reach. However, regulatory restrictions on compounded GLP-1s could limit product availability or increase prices. Cybersecurity incident exposed some PII, potentially impacting trust.
• Employees: Growth in headcount and remote-first policy offer flexibility. Equity incentive programs aim to attract and retain talent. Acquisitions may lead to integration challenges and cultural shifts.
• Providers: Expansion of the provider network and clinical capabilities. Regulatory scrutiny on telehealth and corporate practice of medicine could impact their operational framework and potential liabilities.
• Suppliers/Partners: Increased demand for products and services due to company growth. However, supply chain constraints, particularly for GLP-1s, and regulatory actions against suppliers could disrupt relationships and operations.

Next Steps

• Continue to invest in growth in current offerings and new products and services.
• Expand fulfillment, distribution, and operating capabilities, including Pharmacies, laboratory testing facilities, and peptide manufacturing facility.
• Make significant investments in marketing to acquire new customers.
• Invest in personalized product offerings and compounding capabilities.
• Pursue opportunities to acquire or invest in complementary businesses, services, and technologies.
• Complete the acquisition of Eucalyptus, expected to close in mid-2026.
• Address the FDA warning letters and respond to the FDA statement regarding GLP-1 APIs.
• Cooperate with the DOJ investigation referred by HHS.
• Cooperate with the SEC investigation concerning public statements and disclosures regarding compounded semaglutide.
• Defend against the patent infringement lawsuit filed by Novo Nordisk.
• Make required regulatory and individual notifications regarding the cybersecurity incident on a rolling basis.
• Continue to evaluate the likelihood of achieving performance metrics for CEO stock options and PRSUs on a quarterly basis.
• Potentially repurchase up to $225.0 million of Class A common stock under the 2025 Share Repurchase Program by November 11, 2028.

Key Dates

Recommendation

Hims & Hers demonstrates robust revenue and Adjusted EBITDA growth, driven by successful personalized offerings and strategic international expansion. This indicates strong market demand and effective operational scaling. However, the significant decline in Free Cash Flow, coupled with a barrage of new and serious regulatory investigations from the FDA, HHS, and SEC, along with a patent infringement lawsuit from Novo Nordisk, introduces substantial uncertainty and potential financial liabilities. These legal and regulatory headwinds, particularly concerning compounded GLP-1s, could materially impact future product offerings, operational costs, and brand reputation. While the growth trajectory is compelling, the escalating regulatory and legal risks warrant a cautious 'hold' stance until there is greater clarity on the outcomes and financial implications of these proceedings.

Keywords

Telehealth, Digital Health, Hims & Hers, SEC Filing, 10-K, Financial Results, Revenue Growth, Adjusted EBITDA, Acquisitions, International Expansion, GLP-1, Compounded Drugs, FDA Scrutiny, DOJ Investigation, SEC Investigation, Patent Infringement, Cybersecurity Incident, Healthcare Regulation, Subscription Services, Personalized Medicine, Weight Loss, Dermatology, Sexual Health, Mental Health, Laboratory Testing, Share Repurchase, Corporate Governance